In addition to our innovative drug products based on our proprietary delivery technology, we have a portfolio of generic product candidates with favorable commercial agreements.

In Market

acyclovir cream, 5%
(RLD: ZOVIRAX®)

Sales as of
January 2019

Pending

ivermectin cream, 1%
(RLD: SOOLANTRA®)

Tentative Approval
as of January 2019

halobetasol propionate lotion, 0.01%
(RLD: BRYHALI®)

Filed Paragraph IV
Certification January 2020

halobetasol propionate and tazarotene lotion, 0.01%/0.045%
(RLD: DUOBRII®)

Filed Paragraph IV
Certification June 2020

5-fluorouracil cream, 5%
(RLD: EFUDEX®)

Bioequivalence
Study Completed

All trademarks are the properties of their prospective owners.